MAYNE PHARMA GROUP LIMITED — Capital/Financing Update 2015

Feb 9, 2015

==> picture [104 x 96] intentionally omitted <==

MARKET RELEASE

10 February 2015

Mayne Pharma Group Limited

TRADING HALT

The securities of Mayne Pharma Group Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Thursday, 12 February 2015 or when the announcement is released to the market.

Security Code: MYX

Dean Litis

Principal Adviser, Listings Compliance (Melbourne)

.

10 February 2015

Manager, Company Announcements ASX Limited Rialto Towers Level 45, 525 Collins Street MELBOURNE VIC 3000

Dear Sir/Madam

Mayne Pharma Group Limited – Request for Trading Halt

The directors of Mayne Pharma Group Limited ACN 115 832 963 (ASX: MYX) ( Mayne Pharma ) request a trading halt from the commencement of trading on 10 February 2015 at which time Mayne Pharma proposes to announce an accelerated non-renounceable entitlement offer and institutional placement (together, Capital Raising ) in order to fund a number of growth initiatives including several acquisitions.

The trading halt is requested to facilitate the conduct of a bookbuild for the Capital Raising.

For the purposes of ASX Listing Rule 17.1, Mayne Pharma provides the following further information:

• (a) Mayne Pharma expects that the trading halt remain in place until the commencement of trading on 12 February 2015, unless, before that time, Mayne Pharma requests that the trading halt be lifted; and

• (b) Mayne Pharma is not aware of any reason why the trading halt should not be granted.

If you have any queries, please do not hesitate to contact the writer.

Yours faithfully,

==> picture [152 x 34] intentionally omitted <==

Mark Cansdale Group CFO and Company Secretary

==> picture [581 x 69] intentionally omitted <==